JP5730200B2 - 抗ヘプシジン−２５選択的抗体およびその使用 - Google Patents

抗ヘプシジン−２５選択的抗体およびその使用 Download PDF

Info

Publication number
JP5730200B2
JP5730200B2 JP2011522119A JP2011522119A JP5730200B2 JP 5730200 B2 JP5730200 B2 JP 5730200B2 JP 2011522119 A JP2011522119 A JP 2011522119A JP 2011522119 A JP2011522119 A JP 2011522119A JP 5730200 B2 JP5730200 B2 JP 5730200B2
Authority
JP
Japan
Prior art keywords
hepcidin
antibody
human
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011522119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530514A5 (https=
JP2011530514A (ja
Inventor
ドンミエン・ドーン・マン・レウン
ルアン・ペン
タン・イン
デリック・ライアン・ウィッチャー
ピア・パウリーナ・ヤキ
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2011530514A publication Critical patent/JP2011530514A/ja
Publication of JP2011530514A5 publication Critical patent/JP2011530514A5/ja
Application granted granted Critical
Publication of JP5730200B2 publication Critical patent/JP5730200B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011522119A 2008-08-06 2009-07-29 抗ヘプシジン−２５選択的抗体およびその使用 Expired - Fee Related JP5730200B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8655708P 2008-08-06 2008-08-06
US61/086,557 2008-08-06
PCT/US2009/052044 WO2010017070A1 (en) 2008-08-06 2009-07-29 Anti-hepcidin-25 selective antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2011530514A JP2011530514A (ja) 2011-12-22
JP2011530514A5 JP2011530514A5 (https=) 2013-06-06
JP5730200B2 true JP5730200B2 (ja) 2015-06-03

Family

ID=41165490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522119A Expired - Fee Related JP5730200B2 (ja) 2008-08-06 2009-07-29 抗ヘプシジン−２５選択的抗体およびその使用

Country Status (19)

Country Link
US (1) US8609817B2 (https=)
EP (1) EP2328931B1 (https=)
JP (1) JP5730200B2 (https=)
KR (1) KR101462307B1 (https=)
CN (1) CN102112489B (https=)
AU (1) AU2009279865B2 (https=)
BR (1) BRPI0916624A2 (https=)
CA (1) CA2733497C (https=)
DK (1) DK2328931T3 (https=)
EA (1) EA201170312A1 (https=)
ES (1) ES2432018T3 (https=)
IL (1) IL210643A (https=)
MX (1) MX2011001363A (https=)
NZ (1) NZ590863A (https=)
PL (1) PL2328931T3 (https=)
PT (1) PT2328931E (https=)
UA (1) UA103032C2 (https=)
WO (1) WO2010017070A1 (https=)
ZA (1) ZA201100261B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087760A1 (en) * 2003-04-01 2004-10-14 Inserm (Institut National De La Sante De La Reche Rche Medicale) Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
AR069062A1 (es) * 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
EP3299386A1 (en) 2010-08-16 2018-03-28 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin
AU2012350654C1 (en) 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) * 2012-10-26 2014-05-01 Claresa Levetan Generation of new pancreatic beta cells
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US9816997B2 (en) * 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
WO2016027469A1 (ja) * 2014-08-21 2016-02-25 国立大学法人旭川医科大学 ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016146587A1 (en) 2015-03-13 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
EP3518971A4 (en) 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
AU2017383142A1 (en) 2016-12-22 2019-07-04 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
CN109948371B (zh) * 2019-03-07 2021-06-25 深圳市智税链科技有限公司 为区块链节点发放身份证书的方法及相关装置
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022154121A1 (ja) * 2021-01-18 2022-07-21 富士フイルム和光純薬株式会社 ヘプシジンの吸着抑制剤、吸着抑制方法、標準品、試薬、キットおよび測定方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004522402A (ja) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
EP1392345B2 (en) * 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
RU2359268C2 (ru) 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20050164238A1 (en) 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
US7510842B2 (en) 2005-03-11 2009-03-31 Vermilllion, Inc. Biomarker for ovarian and endometrial cancer: hepcidin
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
ATE553778T1 (de) * 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
AR069062A1 (es) 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use

Also Published As

Publication number Publication date
PL2328931T3 (pl) 2014-01-31
ZA201100261B (en) 2012-06-27
EA201170312A1 (ru) 2012-03-30
EP2328931A1 (en) 2011-06-08
HK1156326A1 (en) 2012-06-08
EP2328931B1 (en) 2013-08-14
BRPI0916624A2 (pt) 2015-12-01
CA2733497A1 (en) 2010-02-11
NZ590863A (en) 2012-10-26
CA2733497C (en) 2015-06-02
IL210643A (en) 2015-09-24
AU2009279865B2 (en) 2013-10-10
IL210643A0 (en) 2011-03-31
MX2011001363A (es) 2011-04-26
UA103032C2 (uk) 2013-09-10
KR101462307B1 (ko) 2014-11-17
CN102112489B (zh) 2014-05-14
US20110189190A1 (en) 2011-08-04
JP2011530514A (ja) 2011-12-22
AU2009279865A1 (en) 2010-02-11
DK2328931T3 (da) 2013-09-30
PT2328931E (pt) 2013-11-07
US8609817B2 (en) 2013-12-17
KR20110031963A (ko) 2011-03-29
WO2010017070A1 (en) 2010-02-11
CN102112489A (zh) 2011-06-29
ES2432018T3 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
JP5730200B2 (ja) 抗ヘプシジン−２５選択的抗体およびその使用
CN112250763B (zh) 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途
JP2015505828A (ja) 抗グルカゴン抗体およびその使用
JP2025020209A (ja) インターロイキン－１９を標的とする化合物および方法
CN101432308A (zh) Fas结合抗体
EP2347004B1 (en) Reagents and methods for detecting the polymorphic protein haptoglobin
TW201927820A (zh) 抗ｐｄ-ｌ１抗體及使用其來偵測ｐｄ-ｌ１之方法
US12590977B2 (en) Anti-ceruloplasmin antibodies and uses thereof
KR20210073785A (ko) 호산구 유래 신경독과 특이적으로 결합하는 단일클론항체 및 이의 용도
HK1156326B (en) Anti-hepcidin-25 selective antibodies and uses thereof
US20250034236A1 (en) Anti-thyroglobulin Antibody, Kit and Use Thereof
WO2026084964A1 (en) Anti-thyroid peroxidase antibodies and immunoassays
US20260125462A1 (en) Compounds and methods targeting interleukin-19
TW201718656A (zh) 用於結合紫杉醇之以抗體為主的親和性試劑
CA3188429A1 (en) Compounds and methods targeting human and mouse insl5
CN116143929A (zh) 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用
HK40040904B (zh) 抗pd-l1抗体及使用其检测pd-l1的方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150407

R150 Certificate of patent or registration of utility model

Ref document number: 5730200

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees